Vaxart Doses First Subject I Phase 1 Trial Of Its Norovirus Vaccine Candidate In Lactating Mothers
Portfolio Pulse from Benzinga Newsdesk
Vaxart has begun dosing the first subject in a Phase 1 trial of its Norovirus vaccine candidate in lactating mothers. This marks a significant step in the development of the vaccine.
November 02, 2023 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Vaxart's initiation of Phase 1 trial for its Norovirus vaccine candidate could potentially boost investor confidence and positively impact the company's stock price in the short term.
The initiation of a Phase 1 trial is a significant milestone in the development of a vaccine. This news could potentially boost investor confidence in Vaxart, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100